Grant: CIHR Fellowship
Direct Payment
$133,333.00
Development of humanized mice to evaluate HIV vaccine candidates
EF 2012-13
Résumé
HIV has infected over 65 000 people in Canada, and 34 million worldwide. In addition to its immediate effects on health, widespread HIV infection has devastating social and economic impacts in the developing world. Some HIV infected individuals generate neutralizing antibodies that bind to HIV and prevent the virus from entering host cells. We are working to generate an HIV vaccine that works by injecting healthy people with non-infectious proteins that trick the immune system into making antibodies that will protect them from HIV; the same way that a flu shot works.
Antibodies are made by specialized cells called B cells. Everybody has millions of different B cells circulating in their blood at any given time, each one can potentially recognize anything foreign, like bacteria or viruses. In order for an HIV vaccine to work the correct B cells must recognize the foreign protein. Once they do, they begin to undergo a number of processes that lead to the production of antibodies against HIV. Previous studies from our lab have shown that HIV proteins are generally not recognized by the correct B cells that will eventually give rise to the kind of protective neutralizing antibodies that we desire to make through vaccination. This may explain why HIV vaccines have failed so far. However, we have recently modified an HIV protein that does engage the correct B cells. If used as part of a vaccine, this modified protein might be capable of generating neutralizing antibodies against HIV. Unfortunately, Human HIV vaccine trials are incredibly expensive and take many years to conduct. As an alternative we are working to transfer B cells found in the human immune system into laboratory mice which we can then use to rather quickly test whether our modified proteins can drive the desired antibody response upon immunization. If this strategy works it would provide justification for moving further towards human clinical trials, and hopefully an effective HIV vaccine.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Washington, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
280844
Name
Mcguire Andrew T
Region
Washington
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of humanized mice to evaluate HIV vaccine candidates
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$133,333
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Adoptive Transfer; Aids; B Cell Physiology; Cell Signalling; Hiv; Immunology; Vaccine
Abstract
HIV has infected over 65 000 people in Canada, and 34 million worldwide. In addition to its immediate effects on health, widespread HIV infection has devastating social and economic impacts in the developing world. Some HIV infected individuals generate neutralizing antibodies that bind to HIV and prevent the virus from entering host cells. We are working to generate an HIV vaccine that works by injecting healthy people with non-infectious proteins that trick the immune system into making antibodies that will protect them from HIV; the same way that a flu shot works.
Antibodies are made by specialized cells called B cells. Everybody has millions of different B cells circulating in their blood at any given time, each one can potentially recognize anything foreign, like bacteria or viruses. In order for an HIV vaccine to work the correct B cells must recognize the foreign protein. Once they do, they begin to undergo a number of processes that lead to the production of antibodies against HIV. Previous studies from our lab have shown that HIV proteins are generally not recognized by the correct B cells that will eventually give rise to the kind of protective neutralizing antibodies that we desire to make through vaccination. This may explain why HIV vaccines have failed so far. However, we have recently modified an HIV protein that does engage the correct B cells. If used as part of a vaccine, this modified protein might be capable of generating neutralizing antibodies against HIV. Unfortunately, Human HIV vaccine trials are incredibly expensive and take many years to conduct. As an alternative we are working to transfer B cells found in the human immune system into laboratory mice which we can then use to rather quickly test whether our modified proteins can drive the desired antibody response upon immunization. If this strategy works it would provide justification for moving further towards human clinical trials, and hopefully an effective HIV vaccine.
Competitiondate
201302
Approvedterm2
2 yrs 8 mths
Pinamesdelim
Mcguire, Andrew T
Approvedterm
2 ans 8 mois
Cihrcontribution2
~ $133,333~ $0~